{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T18:12:00Z","timestamp":1778091120894,"version":"3.51.4"},"reference-count":129,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.rdc.2026.02.008","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:58:26Z","timestamp":1778086706000},"page":"403-422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases"],"prefix":"10.1016","volume":"52","author":[{"given":"Ai Li","family":"Yeo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rdc.2026.02.008_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2026.02.008_bib2","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"135","key":"10.1016\/j.rdc.2026.02.008_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/09059180.00008014","article-title":"Rheumatoid arthritis-associated lung disease","volume":"24","author":"Shaw","year":"2015","journal-title":"Eur Respir Rev"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.008_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0039-1685537","article-title":"Pulmonary complications of systemic lupus erythematosus","volume":"40","author":"Hannah","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"issue":"127","key":"10.1016\/j.rdc.2026.02.008_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1183\/09059180.00005512","article-title":"Scleroderma lung disease","volume":"22","author":"Solomon","year":"2013","journal-title":"Eur Respir Rev"},{"issue":"5","key":"10.1016\/j.rdc.2026.02.008_bib6","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40744-023-00571-z","article-title":"Infections in biological and targeted synthetic drug use in rheumatoid arthritis: where do we stand? A scoping review and meta-analysis","volume":"10","author":"Bergmans","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.008_bib7","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"2011","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"sup1","key":"10.1016\/j.rdc.2026.02.008_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.rdc.2026.02.008_bib9","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.22504","article-title":"Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists","volume":"56","author":"Curtis","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2026.02.008_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11908-009-0034-2","article-title":"Infectious pulmonary complications in patients treated with anti-TNF-alpha monoclonal antibodies and soluble TNF receptor","volume":"11","author":"Carbone","year":"2009","journal-title":"Curr Infect Dis Rep"},{"issue":"21","key":"10.1016\/j.rdc.2026.02.008_bib11","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.rdc.2026.02.008_bib12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/art.42386","article-title":"2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2026.02.008_bib13","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1378\/chest.12-2820","article-title":"Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study","volume":"144","author":"Lanternier","year":"2013","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.rdc.2026.02.008_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.crohns.2008.05.003","article-title":"Pneumonia due to Nocardia cyriacigeorgica in a patient with Crohn\u2019s disease treated with infliximab","volume":"2","author":"Parra","year":"2008","journal-title":"J Crohns Colitis"},{"issue":"11","key":"10.1016\/j.rdc.2026.02.008_bib15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1136\/thx.2006.075150","article-title":"Pulmonary actinomycosis complicating infliximab therapy for Crohn\u2019s disease","volume":"62","author":"Cohen","year":"2007","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.rdc.2026.02.008_bib16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrrheum.2009.279","article-title":"Tumor necrosis factor blockade and the risk of viral infection","volume":"6","author":"Kim","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2026.02.008_bib17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3899\/jrheum.170710","article-title":"A systematic review and meta-analysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis","volume":"45","author":"Subesinghe","year":"2018","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2026.02.008_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41584-022-00755-x","article-title":"COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations","volume":"18","author":"Grainger","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.rdc.2026.02.008_bib19","article-title":"Impact of risk factors on COVID-19 outcomes in unvaccinated people with rheumatic diseases: a comparative analysis of pandemic epochs using the COVID-19 Global Rheumatology Alliance Registry","author":"Yazdany","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.rdc.2026.02.008_bib20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jama.2023.11043","article-title":"Abatacept, cenicriviroc, or infliximab for treatment of adults hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"330","author":"O\u2019Halloran","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.008_bib21","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/art.42372","article-title":"American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5","volume":"75","author":"Curtis","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 3","key":"10.1016\/j.rdc.2026.02.008_bib22","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1086\/429994","article-title":"Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis","volume":"41","author":"Algood","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.008_bib23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.idc.2020.02.011","article-title":"Mycobacterial infections potentiated by biologics","volume":"34","author":"Calabrese","year":"2020","journal-title":"Infect Dis Clin North Am"},{"issue":"6","key":"10.1016\/j.rdc.2026.02.008_bib24","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.008_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/annrheumdis-2011-200690","article-title":"Mycobacterial diseases and antitumour necrosis factor therapy in USA","volume":"72","author":"Winthrop","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.rdc.2026.02.008_bib26","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3201\/eid1510.090310","article-title":"Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy","volume":"15","author":"Winthrop","year":"2009","journal-title":"Emerg Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.rdc.2026.02.008_bib27","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1086\/429996","article-title":"Reactivation of latent granulomatous infections by infliximab","volume":"41","author":"Wallis","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.rdc.2026.02.008_bib28","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.rmed.2005.09.020","article-title":"Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area","volume":"100","author":"Jain","year":"2006","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.rdc.2026.02.008_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11926-016-0572-1","article-title":"Fungal infections and new biologic therapies","volume":"18","author":"Vallabhaneni","year":"2016","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.008_bib30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1086\/648724","article-title":"Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy","volume":"50","author":"Hage","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"49","key":"10.1016\/j.rdc.2026.02.008_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000036450","article-title":"Incidence of histoplasmosis in patients receiving TNF-alpha inhibitors: a systematic review and meta-analysis","volume":"102","author":"Cipolat","year":"2023","journal-title":"Medicine (Baltim)"},{"issue":"3","key":"10.1016\/j.rdc.2026.02.008_bib32","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/cid\/civ299","article-title":"Histoplasmosis complicating tumor necrosis factor-alpha blocker therapy: a retrospective analysis of 98 cases","volume":"61","author":"Vergidis","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.rdc.2026.02.008_bib33","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.20454","article-title":"Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists","volume":"50","author":"Bergstrom","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2026.02.008_bib34","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/cid\/ciy620","article-title":"The utility of screening for coccidioidomycosis in recipients of inhibitors of tumor necrosis factor alpha","volume":"68","author":"Choi","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.rdc.2026.02.008_bib35","doi-asserted-by":"crossref","first-page":"815 e1","DOI":"10.1016\/j.cmi.2016.05.030","article-title":"Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications","volume":"22","author":"Liao","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.rdc.2026.02.008_bib36","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.008_bib37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","article-title":"Fungal infections complicating tumor necrosis factor alpha blockade therapy","volume":"83","author":"Tsiodras","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"18","key":"10.1016\/j.rdc.2026.02.008_bib38","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1056\/NEJMc070728","article-title":"Pneumocystis pneumonia under anti-tumor necrosis factor therapy study G. Pneumocystis pneumonia associated with infliximab in Japan","volume":"357","author":"Harigai","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.rdc.2026.02.008_bib39","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1007\/s10067-021-05660-4","article-title":"Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study","volume":"40","author":"Hsu","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2026.02.008_bib40","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3899\/jrheum.141510","article-title":"Pneumocystis jirovecii pneumonia in Japanese patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a pooled analysis of 3 agents","volume":"42","author":"Tanaka","year":"2015","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2026.02.008_bib41","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1128\/CMR.17.4.770-782.2004","article-title":"Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients","volume":"17","author":"Rodriguez","year":"2004","journal-title":"Clin Microbiol Rev"},{"issue":"7","key":"10.1016\/j.rdc.2026.02.008_bib42","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/art.11154","article-title":"Pulmonary rheumatoid nodules in an etanercept-treated patient","volume":"48","author":"Hubscher","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2026.02.008_bib43","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.21336","article-title":"Granulomatous lung disease occurring during etanercept treatment","volume":"53","author":"Phillips","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.008_bib44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1445-5994.2011.02612.x","article-title":"New-onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication","volume":"42","author":"Tong","year":"2012","journal-title":"Intern Med J"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.008_bib45","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40744-022-00424-1","article-title":"Anti-TNF induced sarcoidosis-like disease in rheumatoid arthritis patients: review cases from the RA UCLouvain Brussels cohort","volume":"9","author":"Theunssens","year":"2022","journal-title":"Rheumatol Ther"},{"issue":"6","key":"10.1016\/j.rdc.2026.02.008_bib46","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.semarthrit.2018.10.005","article-title":"Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety","volume":"48","author":"Adler","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.rdc.2026.02.008_bib47","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/rheumatology\/kep080","article-title":"Anti-TNF-induced lupus","volume":"48","author":"Williams","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.rdc.2026.02.008_bib48","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/rheumatology\/keu214","article-title":"Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case\/non-case study in a nationwide pharmacovigilance database","volume":"53","author":"Moulis","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.rdc.2026.02.008_bib49","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","article-title":"Non-infectious pulmonary toxicity of rituximab: a systematic review","volume":"51","author":"Hadjinicolaou","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.008_bib50","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases","volume":"41","author":"Perez-Alvarez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.008_bib51","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MCG.0000000000000865","article-title":"Risk of cancer recurrence among individuals exposed to antitumor necrosis factor therapy: a systematic review and meta-analysis of observational studies","volume":"53","author":"Micic","year":"2019","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.008_bib52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/rheumatology\/kep329","article-title":"Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor","volume":"49","author":"Dayer","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.008_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002359","article-title":"A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases","volume":"8","author":"Kastrati","year":"2022","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.rdc.2026.02.008_bib54","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/annrheumdis-2017-212825","article-title":"Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British society for Rheumatology biologics register for rheumatoid arthritis","volume":"77","author":"Rutherford","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2026.02.008_bib55","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2026.02.008_bib56","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8909834","article-title":"Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics","volume":"2017","author":"Cantini","year":"2017","journal-title":"Mediators Inflamm"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.008_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13075-022-02842-6","article-title":"Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013-2018","volume":"24","author":"Jung","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.rdc.2026.02.008_bib58","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1136\/ard.2011.151092","article-title":"Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients","volume":"70","author":"Koike","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2026.02.008_bib59","doi-asserted-by":"crossref","first-page":"e490","DOI":"10.1016\/S2665-9913(22)00098-4","article-title":"Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform","volume":"4","author":"MacKenna","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"10285","key":"10.1016\/j.rdc.2026.02.008_bib60","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Group","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.008_bib61","first-page":"318","article-title":"Tocilizumab and the risk of respiratory adverse events in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised controlled trials","volume":"37","author":"Geng","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2026.02.008_bib62","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.rdc.2026.02.008_bib63","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1007\/s00296-010-1525-z","article-title":"A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab","volume":"32","author":"Kawashiri","year":"2012","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.008_bib64","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.semarthrit.2019.03.002","article-title":"Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multi-database cohort study","volume":"49","author":"Kim","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 6","key":"10.1016\/j.rdc.2026.02.008_bib65","doi-asserted-by":"crossref","first-page":"vi9","DOI":"10.1093\/rheumatology\/kez350","article-title":"Anakinra in children and adults with Still\u2019s disease","volume":"58","author":"Vastert","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.rdc.2026.02.008_bib66","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/rheumatology\/kew208","article-title":"Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes","volume":"55","author":"Kullenberg","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2026.02.008_bib67","first-page":"CD005121","article-title":"Anakinra for rheumatoid arthritis","volume":"1","author":"Mertens","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.008_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","article-title":"Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behcet\u2019s disease","volume":"14","author":"Cantarini","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.rdc.2026.02.008_bib69","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2026.02.008_bib70","article-title":"Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study","volume":"64","author":"Simon","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.008_bib71","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/acr.23824","article-title":"Risk of hospitalized infection and initiation of abatacept versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study","volume":"72","author":"Chen","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.008_bib72","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-020-02399-2","article-title":"Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data","volume":"23","author":"Simon","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.rdc.2026.02.008_bib73","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2026.02.008_bib74","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/acr.22470","article-title":"Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy","volume":"67","author":"Yun","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.rdc.2026.02.008_bib75","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.semarthrit.2019.11.010","article-title":"Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: a cohort study","volume":"50","author":"Kang","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2026.02.008_bib76","article-title":"Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study","volume":"64","author":"Simon","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2026.02.008_bib77","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fmed.2020.00303","article-title":"Belimumab and rituximab in systemic lupus erythematosus: a tale of two B cell-targeting agents","volume":"7","author":"Wise","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.rdc.2026.02.008_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1051609","article-title":"Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis","volume":"13","author":"Zhen","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.008_bib79","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semarthrit.2012.12.024","article-title":"Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis","volume":"43","author":"Johnston","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2026.02.008_bib80","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-021-01037-3","article-title":"Long-term safety of rituximab (risks of viral and opportunistic infections)","volume":"23","author":"Varley","year":"2021","journal-title":"Curr Rheumatol Rep"},{"issue":"8","key":"10.1016\/j.rdc.2026.02.008_bib81","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/acr.23781","article-title":"Long-term safety of rituximab in rheumatoid arthritis: analysis from the SUNSTONE registry","volume":"71","author":"Winthrop","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.rdc.2026.02.008_bib82","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2665-9913(21)00059-X","article-title":"COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study","volume":"3","author":"Avouac","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2026.02.008_bib83","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2026.02.008_bib84","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.42058","article-title":"Rituximab impairs B cell response but not T cell response to COVID-19 vaccine in autoimmune diseases","volume":"74","author":"Bitoun","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2026.02.008_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(23)00336-1","article-title":"SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis","author":"Raglow","year":"2024","journal-title":"Lancet Microbe"},{"issue":"12","key":"10.1016\/j.rdc.2026.02.008_bib86","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/art.42287","article-title":"Breakthrough SARS-CoV-2 infections in patients with immune-mediated disease undergoing B cell-depleting therapy: a retrospective cohort analysis","volume":"74","author":"Calabrese","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.008_bib87","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1016\/S2665-9913(23)00004-8","article-title":"Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study","volume":"5","author":"Md Yusof","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.rdc.2026.02.008_bib88","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.rdc.2026.02.008_bib89","article-title":"Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying antirheumatic drugs: does line of therapy matter?","author":"Lauper","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2026.02.008_bib90","article-title":"Incidence of Pneumocystis jiroveci pneumonia in patients with ANCA-associated vasculitis initiating therapy with rituximab or cyclophosphamide","author":"Nettleton","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.rdc.2026.02.008_bib91","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/ard-2022-223401","article-title":"Risk factors for serious infections in ANCA-associated vasculitis","volume":"82","author":"Odler","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2026.02.008_bib92","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/cid\/ciaa127","article-title":"Serious infectious events and Immunoglobulin replacement therapy in patients with autoimmune disease receiving rituximab: a retrospective cohort study","volume":"72","author":"Stabler","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.008_bib93","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40744-019-00183-6","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with rituximab: analyses of global postmarketing safety data and long-term clinical trial data","volume":"7","author":"Emery","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"16","key":"10.1016\/j.rdc.2026.02.008_bib94","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"issue":"11\u201312","key":"10.1016\/j.rdc.2026.02.008_bib95","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1177\/13524585231195346","article-title":"Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension","volume":"29","author":"Hauser","year":"2023","journal-title":"Mult Scler"},{"issue":"11","key":"10.1016\/j.rdc.2026.02.008_bib96","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1177\/09612033211028653","article-title":"10 years of belimumab experience: what have we learnt?","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"issue":"13","key":"10.1016\/j.rdc.2026.02.008_bib97","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1177\/09612033221131183","article-title":"Safety of belimumab in adult patients with systemic lupus erythematosus: results of a large integrated analysis of controlled clinical trial data","volume":"31","author":"Wallace","year":"2022","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.rdc.2026.02.008_bib98","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/art.42620","article-title":"Comparative risks of infection with belimumab versus oral immunosuppressants in patients with nonrenal systemic lupus erythematosus","volume":"75","author":"Materne","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2026.02.008_bib99","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.40861","article-title":"Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus","volume":"71","author":"Wallace","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2026.02.008_bib100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.008_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000464","article-title":"Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials","volume":"8","author":"Tummala","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.008_bib102","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2026.02.008_bib103","article-title":"Risk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sources","volume":"13","author":"Davidson","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.008_bib104","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","article-title":"Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis","volume":"79","author":"Li","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2026.02.008_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1294416","article-title":"Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.rdc.2026.02.008_bib106","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1111\/1346-8138.13986","article-title":"Secukinumab-induced interstitial pneumonia in a patient with psoriasis vulgaris","volume":"44","author":"Kajihara","year":"2017","journal-title":"J Dermatol"},{"issue":"7","key":"10.1016\/j.rdc.2026.02.008_bib107","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/ced.14259","article-title":"The risk of interstitial lung disease during biological treatment in Japanese patients with psoriasis","volume":"45","author":"Matsumoto","year":"2020","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"10.1016\/j.rdc.2026.02.008_bib108","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/acr.24630","article-title":"Risk of hospitalization for serious infection after initiation of ustekinumab or other biologics in patients with psoriasis or psoriatic arthritis","volume":"74","author":"Jin","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.rdc.2026.02.008_bib109","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/ibd\/izaa236","article-title":"Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2\/3 studies","volume":"27","author":"Sandborn","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.rdc.2026.02.008_bib110","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000002621","article-title":"Efficacy and safety of ustekinumab for ulcerative colitis through 4 Years: final results of the UNIFI long-term maintenance study","author":"Afif","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"14","key":"10.1016\/j.rdc.2026.02.008_bib111","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/ajhp\/zxab156","article-title":"Diffuse alveolar hemorrhage associated with ustekinumab treatment","volume":"78","author":"Gunasekaran","year":"2021","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.008_bib112","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/bjd\/ljad115","article-title":"Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure","volume":"189","author":"Lebwohl","year":"2023","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2026.02.008_bib113","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2026.02.008_bib114","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","volume":"186","author":"Gordon","year":"2022","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.rdc.2026.02.008_bib115","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.008_bib116","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.cgh.2020.12.030","article-title":"Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease","volume":"20","author":"Kirchgesner","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1S Suppl 1","key":"10.1016\/j.rdc.2026.02.008_bib117","doi-asserted-by":"crossref","first-page":"e1057","DOI":"10.1097\/MEG.0000000000002197","article-title":"Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis","volume":"33","author":"Rizos","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.rdc.2026.02.008_bib118","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2026.02.008_bib119","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/rheumatology\/keaa117","article-title":"Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis","volume":"59","author":"Khoo","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.rdc.2026.02.008_bib120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The infection risks of JAK inhibition","volume":"18","author":"Adas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"10.1016\/j.rdc.2026.02.008_bib121","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.008_bib122","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","article-title":"Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2026.02.008_bib123","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2026.02.008_bib124","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.rdc.2026.02.008_bib125","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2026.02.008_bib126","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2026.02.008_bib127","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.rdc.2026.02.008_bib128","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/ard-2023-224816","article-title":"Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial","volume":"83","author":"Geetha","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2026.02.008_bib129","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003435","article-title":"Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan","volume":"9","author":"Aqeel","year":"2023","journal-title":"RMD Open"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X26000086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X26000086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T17:29:02Z","timestamp":1778088542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X26000086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":129,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0889857X26000086"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2026.02.008","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2026.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}